UBS Initiated Hospira at Sell, $25 PT
UBS has initiated coverage on Hospira (NYSE: HSP) with a Sell rating and $25 price target.
(c) 2012 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
We're Loving
Benzinga's Premium Memberships
-
Options & Volatility Edge
Options & Volatility Edge is for those people who want to make money using cost effective options trading strategies. This product is for anyone—novices and experts. If you understand how to enter an options trade, you need Options & Volatility Edge.
-
ETF Professor
The ETF Professor is truly an appropriate moniker, because the Professor spends hours everyday analyzing the charts of dozens of ETFs EVERY DAY.
-
Winning Stocks
Winning Stocks tracks and analyzes attractive stocks that are poised to make great returns for the average investor. Investors receive the right information at the right time, which provides them with the possibility for great gains and the potential to beat the market.
-
Real-Time Rumors
In this game, information is everything. You have to know what is happening before the Street begins trading against you utilizing the new information. We will provide you with that edge.
-
Chart-Caster
From novice to pro, Chart-Caster delivers over $11,000 per month* in profitable trade setups across all time-frames from which members can evaluate, select, and replicate within their own trading accounts.
From Benzinga's Newsdesk
- 04:52 PM German Solar Power Plants Produce 50% of the Nation's Electric Energy On Saturday
- 11:50 AM Research in Motion to Eliminate 2,000 Jobs -Globe and Mail
- 07:55 PM Klafter Olsen & Lesser Files Class Action against Facebook
- 7:17 PM Amarin Patent 598 to Be Announced as Officially Issued on May 29
- 05:05 PM Rite Aid Names John T. Standley Board Chairman
- 4:45 PM Quest Software Spokesperson is Not Commenting on Report of Deal with Dell as Early as This Weekend
- 4:43 PM DepoMed Files $100M Mixed Securities Shelf
- 04:37 PM Albemarle to Increase Ibuprofen Prices
- 04:34 PM Tranzyme Announces Data Show ULISES 008 Did Not Meet Primary and Secondary Endpoints
- 4:32 PM BG Medicine Files $75M Mixed Securities Shelf
- 4:30 PM BioFuel Energy to do a 1:20 Reverse Split on or Before June 15
- 4:26 PM Shelia Bair on CNBC Says JPMorgan Just Too Complex
- 4:20 PM Dell Spokesperson Declines Comment on Chatter of Quest Software Deal Announcement this Weekend
- 04:08 PM NASB Financial Announces Consent Order
- 4:06 PM UPDATE: Icahn Says Board Failed to Hold Management Accountable
Brain Trust
- German Solar Power Plants Produce 50% of the Nation's Electric Energy On Saturday
- Research in Motion to Cut Thousands of Jobs
- Klafter Olsen & Lesser Files Class Action against Facebook
- Rite Aid Names John T. Standley Board Chairman
- Albemarle to Increase Ibuprofen Prices
- Tranzyme Announces Data Show ULISES 008 Did Not Meet Primary and Secondary Endpoints
- Corporate Raider Carl Icahn Strikes Again, Achieves 7.56% Stake in Chesapeake
- NASB Financial Announces Consent Order
- Insignia Systems Appoints Glen Dall as President
- ZaZa Energy Announces Receipt of NASDAQ Notification Letter
- 4 Smaller Alternatives to Big Pharma Obesity Treatments
- Apple Fans Want a Product the Company Won't Make
- Delcath Prices $20 Million Public Offering of Common Stock and Warrants
- Bank of America Comments on Settlement Talks for Idenix Pharmaceuticals
- Could Sodastream Face the Same Fate as Green Mountain?
- Stocks in Motion: GSV Capital, Zynga
- Piper Jaffray Comments on April Sales Data for Mattress Industry
- Benzinga's Top Pre-Market Gainers
- JC Penney Strength Attributed to Unconfirmed Rumors
- Earnings Scheduled For May 25
